hrp0092fc7.2 | Diabetes and Insulin Session 2 | ESPE2019

Copeptin Kinetics and its Relationship to Osmolality During Rehydration for Diabetic Ketoacidosis in Children: An Observational Study

Burckhardt Marie-Anne , Beglinger Svetlana , Gotta Verena , Renggli Luzia , Bachmann Sara , Hess Melanie , Rentsch Katharina , Koch Gilbert , Zumsteg Urs , Jones Timothy , Pfister Marc , Szinnai Gabor

Background: Copeptin is a surrogate marker for arginine vasopressin (AVP) release in response to hyperosmolal stimuli such as diabetic ketoacidosis (DKA). We aimed to characterize the temporal course (kinetics) of serum osmolality and copeptin during rehydration and insulin therapy in children with type 1 diabetes (T1D) and DKA, and the relationship between both (dynamics).Methods: An observational multi-center study was...

hrp0094fc4.3 | Diabetes | ESPE2021

Aldosterone and pro-atrial natriuretic peptide kinetics in response to rehydration in children with diabetic ketoacidosis

Burckhardt Marie-Anne , Otto Marije , Gotta Verena , Beglinger Svetlana , Bachmann Sara , Hess Melanie , Rentsch Katharina , Koch Gilbert , Davis Elizabeth , Zumsteg Urs , Jones Tim , Pfister Marc , Szinnai Gabor ,

Background: Diabetic ketoacidosis (DKA), a frequent complication of type 1 diabetes (T1D), is characterized by hyperosmolar hypovolemia. The response of water-regulating hormones to DKA treatment in children is not well known. While arginine vasopressin (AVP) is thought to respond to changes in osmolality, aldosterone and atrial natriuretic peptide (ANP) are expected to respond to volume changes (dehydration and overhydration, respectively). The objective of t...

hrp0094p2-453 | Thyroid | ESPE2021

Kinetics of FT4 serum concentrations in newborns and infants with congenital hypothyroidism during follow-up differ in the three severity groups

Steffens Britta , Gächter Pascal , Koch Gilbert , l'Allemand Dagmar , Janner Marco , Konrad Daniel , Welzel Tatjana , Pfister Marc , Szinnai Gabor

Background: The goal of congenital hypothyroidism (CH) treatment is rapid normalization and maintenance of TSH and FT4 in the reference range. Recommended starting dose of levothyroxine (LT4) ranges from 10-15 mg/kg/d. Hyperthyroxinemia can be accepted in the context of normal TSH and LT4 should only be reduced in case of symptoms or repeatedly increased FT4. The aim of this study was to quantify duration and maximum peak of FT4 levels outside the reference range for each CH s...